Theressa J. Wright

Adverse Mortality Effect of Central Sympathetic Inhibition with Sustained-Release Moxonidine in Patients with Heart Failure (MOXCON)

Jay N. Cohn, Marc A. Pfeffer, Jean L. Rouleau et al. · European Journal of Heart Failure · 2003 · 378 citations

Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: Further evidence for survival and safety and implications for early treatment*

Jean‐Louis Vincent, Gordon R. Bernard, Richard Beale et al. · Critical Care Medicine · 2005 · 320 citations

Safety and dose relationship of recombinant human activated protein C for coagulopathy in severe sepsis

Gordon R. Bernard, E. Wesley Ely, Theressa J. Wright et al. · Critical Care Medicine · 2001 · 271 citations

Low Levels of Protein C Are Associated With Poor Outcome in Severe Sepsis

S. Betty Yan, Jeffrey D. Helterbrand, Daniel Hartman et al. · CHEST Journal · 2001 · 257 citations

Inflammation, Severe Sepsis, Poor Outcome +7

Design and methods of the Raloxifene Use for The Heart (RUTH) study

Lori Mosca, Elizabeth Barrett‐Connor, Nanette K. Wenger et al. · The American Journal of Cardiology · 2001 · 166 citations

Heart Failure, Raloxifene Use, Cardiovascular Disease +7